INTRODUCTION
Pioglitazone (PGZ) is an oral hypoglycemic agent used in the treatment of type II diabetes which acts by decreasing insulin resistance. PGZ freebase and its hydrochloride salt have very low aqueous solubilities, and the hydrochloride salt (PGZ-HCl) is used in the pharmaceutical formulations. The aqueous solubilities of PGZ freebase were investigated by Seedher and Kanojia (1,2) in water, surfactant containing solutions, and as a function of pH in buffer solutions. They reported solubilities in water, 0.039 mM; 58.00 mM sodium dodecyl sulfate (SDS), 1.171 mM; 51.00 mM cetyl triethylammonium bromide (CTAB), 0.232 mM; 51 mM polysorbate 80 (PS80), 0.252 mM; SDS + PS80, 1.588 mM; and CTAB + PS80, 0.498 mM. To our knowledge, no solubility data have been reported in the literature for the hydrochloride or any other salt of PGZ.
Our intent was to measure the solubilities of PGZ-HCl in a series of aqueous cosolvent systems containing ethanol, propylene glycol, and N-methyl-2-pyrrolidone (NMP) at 298.2°K which extends the available database (3) of drugs solubilities in mixed solvents, fitting the data to the JouybanAcree model (4) that relates the solubilities in solvent mixtures to the fractions of the solvent components and constants computed by regression analysis. The JouybanAcree and several other cosolvency models have been reviewed and compared (4) . This model has been used in predicting the solubilities of many pharmaceutical and chemical compounds in binary and ternary solvent mixtures at different temperatures. It has also been used to calculate several physicochemical properties in mixed solvent systems (4).
EXPERIMENTAL METHODS

Materials
PGZ-HCl (99.8% w/w) was purchased from Osveh Pharmaceutical Company (Tehran, Iran). Propylene glycol (99.5%), ethanol (99.9%), and NMP (99.5% w/w) were purchased from Merck (Germany), methanol (99.8% w/w) was purchased from Caledon (Canada), and double distilled water was used for preparation of the solutions.
Apparatus and Procedures
The binary mixtures composed of cosolvent + water with suitable volumes of the solvents were prepared with the accuracy of 0.001 volume fraction. The solubilities of PGZ-HCl were determined by the saturation shake-flask method of Higuchi and Connors (5) . Briefly, an excess amount of the drug was added to the prepared solvent mixtures. The resulting solutions were equilibrated for at least 3 days on a shaker (Behdad, Tehran, Iran) in an incubator equipped with a temperature-controlling system maintained constant at 298.2°K (±0.2). The saturated solutions were filtered using hydrophilic Durapore (polyvinylidene fluoride membrane with a cellulose ester (RW06) prefilter) filters (0.45 μm, Milipore, Ireland) and diluted with methanol. Diluted samples were then assayed at 267 nm (molar absorptivity of 7,464 to 7,537 L mol −1 cm −1 ) using an ultraviolet-visible spectrophotometer (Beckman DU-650, Fullerton, USA). Preliminary investigations showed that the filter did not absorb the solute during the filtration process. The concentration of each solution was determined with an absorbance versus concentration calibration curve (absorbance = 21.086 × concentration − 0.0066) after appropriate dilution. Each experimental data point represents the average of at least three repetitive measurements with the measured mole per liter (M) solubilities being reproducible within ±4.2%. Densities of the saturated solutions were determined using a 5-mL pycnometer.
Computational Methods
The general form of the Jouyban-Acree model for calculating the solubilities of drugs in binary solvent mixtures at different temperatures is (4): The model requires knowledge of the solubility of drug in both monosolvents and in several binary solvent mixtures in order to calculate the model constants. By assuming similar solute-solvent interactions for various drugs, trained versions of the Jouyban-Acree model have been reported for aqueous-ethanol and aqueous-propylene glycol mixtures at various temperatures. There is insufficient published solubility data for crystalline solutes dissolved in NMP + water mixtures to obtain significant model constants for this binary solvent system. Using the trained version for ethanol + water mixtures (6):
and for propylene glycol + water mixtures (7): The mean percentage deviation (MPD) was used to check the accuracy of the fitted and predicted values and was calculated using:
where N is the number of data points in each set. Table I lists the experimental solubilities of PGZ-HCl in binary mixtures of ethanol + water, NMP + water, and propylene glycol + water at 298.2°K. Considering the aqueous solubility datum of PGZ-HCl (0.7 mM), it is evident that the salt form of PGZ is 18 times more soluble than the base form of PGZ (0.039 mM). Addition of the cosolvents increased the solubility of PGZ-HCl with different patterns. For ethanol + water mixtures, the solubility of PGZ-HCl was found to initially increase with increasing volume fraction of ethanol. A maximum solubility of C Sat m;max ¼ 209:3 mM was obtained at 8 1 =0.80 (see Fig. 1 ). This type of the solubility profile is very common for water-ethanol mixtures and could be justified considering the Hildebrand solubility approach in which the maximum solubility value could be observed when the solubility parameters of the solvent and the solute are the same. A slightly different pattern is observed for NMP + water mixtures, in which the maximum solubility value (C Sat m;max ¼ 730:9 mM ) is obtained at φ 1 =0.90 (see Fig. 2 ). An increased solubility pattern is observed for PGZ-HCl in propylene glycol + water mixtures, and the maximum solubility value (C Sat m;max ¼ 113:2 mM ) is obtained in neat propylene glycol (see Fig. 3 ). Considering the solubilization power definitions from the literature, i.e., Eqs. 5 (8) and 6 (9): is the maximum observed solubility, and 8 1 , max denotes the fraction of the cosolvent producing the maximum solubility. In the numerical values σ and ω for the cosolvents (as listed in Table II) , the solubilization power of NMP is greater than that of propylene glycol, and the lowest power is for ethanol when σ definition is concerned. The order of the solubilization power of the cosolvents is NMP, followed by ethanol and propylene glycol, considering the ω definition. This order is confirmed by the experimental solubility data of PGZ-HCl in cosolvent + water mixtures.
RESULT AND DISCUSSION
Comparing the solubilization of PGZ using micelles, it is found that these agents are increased the solubility of PGZ by a factor of 12.8 (for the best data reported by Seedher and Kanojia (1)). The reported solubility data of PGZ in 8 1 =0.20 and 8 1 =0.40 ethanol were 0.62 and 14.76 mM, respectively (2) . The corresponding values for propylene glycol were 0.39 and 28.30 mM. It is not possible to compare these data points with our generated data, however, we could conclude that using salt form and cosolvent could provide better solubilization results, and for low concentration of the cosolvent, propylene glycol acts better than ethanol for both PGZ and PGZ-HCl. (8 1 ) in binary solvent mixtures at 298.2°K with the error bars (dots) and the back-calculated solubility using Eq. 1 (broken line) and Eq. 2 (straight line) (8 1 ) in binary solvent mixtures at 298.2°K with the error bars (dots) and the back-calculated solubility using Eq. 1 (broken line) and Eq. 3 (straight line) The measured experimental solubility data were fitted to Eq. 1, the model constants computed, and the backcalculated solubility data used to compute the MPD values. The calculated MPDs along with the model constants are listed in Table III . The model provides a very good mathematical description of the experimental solubility data, and the overall MPD is 11.6%. Using the model constants (J 0 , J 1 , and J 2 ) listed in Table III , it is possible to predict the solubility of PGZ-HCl in aqueous mixtures of ethanol, NMP, and propylene glycol at all composition ranges, and the expected prediction errors are 13.8%, 13.6%, and 7.5%, respectively. The constants of Eq. 1 were calculated using nine to 14 data points, and calculations based on this equation represent back-calculations in that the measured experimental data are used to calculate the model constants. As noted above, these calculations could be used to predict the solubility of PGZ-HCl at all solvent composition ranges of watercosolvent mixtures and also to detect possible outliers where redeterminations are required. Calculations using Eqs. 2 and 3, on the other hand, represent outright predictions and require only a prior knowledge of C In many chemical/pharmaceutical processes, the mole fraction solubilities are required, and to provide the possibility of unit conversion, the density of the saturated solutions were measured and listed in Table IV .
SUMMARY AND CONCLUSION
Solubility of drugs is a limiting factor to develop liquid drug formulations and also to improve their bioavailability. One of the common methods to increase the aqueous solubility of low soluble drugs is to use the salt forms of drugs. Using hydrochloride form of PGZ, the aqueous solubility is increased from 0.04 (1,3) to 0.7 mM. PGZ-HCl is still a low soluble drug, and additional solubilization method should be employed. In this work, experimental molar solubility and the density of the saturated solutions of PGZ-HCl in aqueous binary mixtures of ethanol, NMP, and propylene glycol at 298.2°K were reported. The solubility of PGZ-HCl was increased with the addition of the cosolvents, and the maximum solubilities are observed at 0.80, 0.90, and 1.00 volume fractions of the cosolvents, respectively. In order to provide a computational method to calculate the solubilities, the Jouyban-Acree model was fitted to the results of these measurements, and solubilities were back-calculated with employing the solubility data in monosolvents in which the overall mean deviation of the models was 11.6%. Two previously trained version of the model were used to predict the solubility of PGZ-HCl in water-cosolvent mixtures employing the experimental solubility data in monosolvents in which the overall prediction error was 57.0%.
ACKNOWLEDGMENTS
We thank Osveh Pharmaceutical Company for supplying the powdered drug. The financial support under grant no. NSM63-50 of Research Center for Pharmaceutical Nanotechnology is gratefully acknowledged. 
